Le Lézard
Classified in: Health, Business
Subjects: CON, CFG, MAT

Health Canada Leverages Strainprint(R) Technologies' Real-Time Observational Data and Analytics to Better Understand Cannabis Use in Canada


Strainprint Analytics Research Platform to Help Support Canadian Government
Policies Post-Cannabis Legalization

TORONTO, Oct. 15, 2019 /PRNewswire/ - StrainprintR Technologies Ltd. (Strainprint), the leader in cannabis data and analytics is proud to announce that Health Canada has subscribed to use Strainprint Analytics to further research Canadians' use of cannabis in the post-legalization era.

Strainprint Technologies Ltd. (CNW Group/Strainprint Technologies Ltd.)

Health Canada views the legalization and regulation of all cannabis through a lens of public safety and is regarded as one of the most respected regulatory bodies in the world. Raising awareness about the health effects of cannabis through research and public education is fundamental to Health Canada's mandate, which Strainprint's real-world observational data is uniquely positioned to support.

Health Canada now has access to over 1.4 million anonymized patient reported outcomes (70+ million data points on real-time patient use and strain efficacy) through Strainprint Analytics, the most sophisticated cannabis research platform available today. Strainprint Analytics is the self-serve web-companion to published reports (like the Canadian Medical Cannabis Experience: A 2019 Patient Retrospective) and custom research that Strainprint's research team conducts on its data for industry.

Various departments at Health Canada will use Strainprint Analytics to:

"Canada has developed the most sophisticated and compliant medical cannabis program in the world, which makes Health Canada, arguably, one of the most important data customers in the industry," said Strainprint CEO, Andrew Muroff. "We are incredibly proud that they have chosen to work with us as a trusted authority on patient data."

For more information visit www.strainprintanalytics.com.

About StrainprintR
Founded in Toronto in 2016, StrainprintR Technologies Ltd. is the leading demand-side cannabis data and analytics company. With the world's largest longitudinal, observational dataset of its kind and a mission to advance the scientific understanding of cannabis and its legitimization as a mainstream therapy, Strainprint helps medical cannabis patients and doctors to use cannabis in the most effective and responsible way possible. Strainprint's comprehensive research platform provides advanced business intelligence and treatment guidance to producers, retailers, medical practitioners, pharmacies, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted, and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. Strainprint Analytics is accessed by customer subscription. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and Google Play Store. www.strainprint.ca, facebook, twitter, linkedin. Strainprint Reports are available at https://strainprint.ca/strainprint-reports/.

For Further Information
Jessica Moran
Director of Marketing & Communications
519-494-5379
[email protected]

SOURCE Strainprint Technologies Ltd.


These press releases may also interest you

at 06:08
ConTemporary Locums, a physician-focused medical staffing company, is ushering in a new era with a bold rebrand: Era Locums. This brand evolution marks a commitment to continued innovation and a deeper connection with the company's physician and...

at 06:05
AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March 25-31 as National Physicians Week. This week and throughout the year, we celebrate the dedication of physicians who selflessly...

at 06:00
The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's...

at 05:45
The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to  ResearchAndMarkets.com's offering....

at 05:45
The Gross Law Firm issues the following notice to shareholders of InMode Ltd. . Shareholders who purchased shares of INMD during the...

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...



News published on and distributed by: